AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: A budget impact analysis

ClinicoEconomics and Outcomes Research

Volumn 7, Issue , 2015, Pages 441-449

  Abogunrin, Seye ^a   Brand, Sarah ^b   Desai, Kamal ^a   Dinet, Jerome ^c   Gabriel, Sylvie ^d   Harrower, Timothy ^e  

^a EVIDERA   (United Kingdom)

^b EVIDERA   (United States)

^c Health Economics and Outcomes Research (Global)   (United Kingdom)

^d IPSEN   (France)

^e ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Botulinum toxin A; Budget impact analysis; Cervical dystonia; Torticollis

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; MUSCLE RELAXANT AGENT;

ARTICLE; CERVICAL DYSTONIA; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG RESPONSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH IMPACT ASSESSMENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PALLIATIVE THERAPY; PATIENT CARE; PREVALENCE; UNITED KINGDOM;

EID: 84941625732     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S86355     Document Type: Article

References (29)

1. Bloudek L, Stacy M, Schwartz M, Brin M, Papapetropoulos S. Cost of cervical dystonia in the United States [abstract]. Movement Disorders. 2012;27 Suppl 1:1005.
2. Coelho M, Valdas AF, Mestre T, Ferreira JJ. Pain and quality of life in the treatment of cervical dystonia. European Neurological Review. 2009;4(2):74-78.
3. Marras C, Van den Eeden SK, Fross RD, et al. Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology. 2007;69(7):676-680.
4. Velickovic M, Benabou R, Brin MF. Cervical dystonia pathophysiology and treatment options. Drugs. 2001;61(13):1921-1943.
5. Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012;27(14):1789-1796.
6. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000;247(10):787-792.
7. Albanese A, Asmus F, Berardelli A, et al; EFNS MDS-ES Task Force. Guidelines for the Diagnosis and Treatment of Primary (Idiopathic) Dystonia. EFNS MDS-ES Task Force. Available from http://www.movementdisorders.org/MDS-Files1/MDS-ES/guidelines_on_dystonia.pdf. Accessed December 14, 2012.
8. The National Institute for Health and Clinical Excellence (NICE). Selective Peripheral Denervation for Cervical Dystonia. London, UK: The National Institute for Health and Clinical Excellence; 2004.
9. Walker FO. Botulinum toxin therapy for cervical dystonia. Phys Med Rehabil Clin N Am. 2003;14(4):749-766, vi.
10. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006;9(2-3):145-148.
11. Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258(9):1670-1675.
12. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001;71(2):193-199.
13. Skogseid IM, Malt UF, Røislien J, Kerty E. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol. 2007;14(10):1129-1137.
14. Slawek J, Friedman A, Potulska A, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol. 2007;22(2): 95-100.
15. Skogseid IM, Røislien J, Claussen B, Kerty E. Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord. 2005;20(12):1604-1609.
16. Molho ES, Agarwal N, Regan K, Higgins DS, Factor SA. Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord. 2009;24(9):1384-1387.
17. Brockmann K, Schweitzer K, Beck G, Wachter T. Comparison of dif-ferent preparations of botulinumtoxin A in the treatment of cervical dystonia. Neurology Asia. 2012;17:115-119.
18. British National Formulary [webpage on the Internet]. Joint Formulary Committee. British National Formulary; 2012. Available from: https://www.medicinescomplete.com/mc/bnf/current/. Accessed December 14, 2012.
19. Personal Social Services Research Unit [webpage on the Internet]. Unit costs of health and social care 2011: compiled by Lesley Curtis. Kent, UK: Personal Social Services Research Unit; 2011. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2011/index.php. Accessed December 14, 2012.
20. Erjanti H, Marttila R, Rinne U. The prevalence and incidence of cervical dystonia in south-western Finland. Mov Disord. 1996; 11(Suppl 1):A215.
21. The Dystonia Society [webpage on the Internet]. Cervical dystonia. London, UK: The Dystonia Society; 2014. Available from: http://www.dystonia.org.uk/index.php/professional-research/types-of-dystonia/cervical-dystonia. Accessed June 2, 2014.
22. MHRA. Dysport Powder for Solution for Injection and Botulinum Toxin Type A Powder for Solution for Injection (Clostridium botulinum Type A Toxin-Haemagglutinin Complex). PL 34926/0014 and 0015. Slough, UK: UKPAR; 2011. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con108612.pdf. Accessed July 22, 2014.
23. MHRA. Botox (Botulinum Toxin Type A). PL 00426/0074-0110, PL 00426/0118-0030, PL 00426/0119-0012. Slough, UK: UKPAR; 2012. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con208720.pdf. Accessed July 22, 2014.
24. MHRA. Xeomin 100 LD50 Units Powder for Solution for Injection. Slough, UK: UKPAR 2012. Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1427432040685.pdf. Accessed July 22, 2014.
25. Han Y, Stevens A, Dashtipour K, Hauser R, Mari Z. A mixed treatment comparison (Mtc) to compare the efficacy of botulinum toxin type A treatments for cervical dystonia. Value Health. 2014;17(3):A57.
26. Albanese A, Abbruzzese G, Dressler D, et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol. Epub 2015 April 1.
27. Hubble J, Schwab J, Hubert C, Abbott CC. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes. Clin Neuropharmacol. 2013; 36(4):122-127.
28. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord. 2005; 20(8):937-944.
29. Misra VP, Ehler E, Zakine B, Maisonobe P, Simonetta-Moreau M; INTEREST IN CD group. Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open. 2012;2(3). pii: e000881.